UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of
earliest event reported):
September
24, 2003
|
BIOSANTE PHARMACEUTICALS, INC. |
||||
|
(Exact name of registrant as specified in its charter) |
||||
|
|
||||
|
Delaware |
|
0-28637 |
|
58-2301143 |
|
(State or Other
Jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification |
|
|
||||
|
111 Barclay Boulevard |
|
60069 |
||
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
|
|
||||
|
|
||||
|
(847) 478-0500 |
||||
|
(Registrant’s Telephone Number, Including Area Code) |
||||
|
|
||||
|
N/A |
||||
|
(Former Name or Former Address, If Changed Since Last Report) |
||||
Item 5. Other Events
On September 25, 2003, BioSante Pharmaceuticals, Inc. issued a press release, a copy of which is attached as an exhibit hereto, announcing that on the evening of September 24, 2003, BioSante Pharmaceuticals, Inc. received a notice that it was approved for listing on the American Stock Exchange and expects that its common stock will begin trading on the American Stock Exchange under the ticker symbol “BPA” at the opening of trading on October 1, 2003. Our common stock will continue to trade on the Over-the-Counter Bulletin Board under the ticker symbol “BISP” until the closing of trading on September 30, 2003.
Item 7. Financial Statements and Exhibits.
|
(a) |
Financial Statements of Businesses Acquired. |
||
|
|
|
||
|
|
Not Applicable |
||
|
|
|
||
|
(b) |
Pro Forma Financial Information. |
||
|
|
|
||
|
|
Not Applicable |
||
|
|
|
||
|
(c) |
Exhibits. |
||
|
|
|
||
|
|
Exhibit No. |
|
Description |
|
|
|
|
|
|
|
Ex. 99.1 |
|
Press Release dated September 25, 2003 (filed herewith electronically). |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: September 25, 2003 |
BIOSANTE PHARMACEUTICALS, INC. |
||
|
|
|||
|
|
|||
|
|
By: |
/s/ Phillip B. Donenberg |
|
|
|
|
Phillip B. Donenberg |
|
|
|
|
Chief Financial Officer, Treasurer and Secretary |
|
3
BIOSANTE PHARMACEUTICALS, INC.
FORM 8-K
Exhibit Index
|
Exhibit |
|
Description |
|
Method of Filing |
|
|
|
|
|
|
|
99.1 |
|
Press Release of BioSante Pharmaceuticals, Inc. issued September 25, 2003. |
|
Filed herewith electronically |
4